Experience
Our clinical development and post-approval track record, by study type and therapeutic area.
Clinical development / post-approval stages
Experience across study types and therapeutic areas
| Type | Share |
|---|---|
| Phase 1 | 13% |
| Phase 2 | 12% |
| Phase 3 | 12% |
| Phase 4 | 3% |
| PMS | 5% |
| OS | 7% |
| IIT | 7% |
| HFF & Cosmetic | 4% |
| Medical Device | 23% |
| Others | 14% |
| Therapeutic area | Share |
|---|---|
| Dermatology | 16% |
| Endocrinology | 15% |
| Cardiology | 12% |
| Gastroenterology | 10% |
| Others | 7% |
| Pulmonology | 6% |
| Ophthalmology | 5% |
| Neurology | 4% |
| E.N.T. | 4% |
| Hepatology | 3% |
| Orthopedics | 3% |
| Hematology | 2% |
| Oncology | 2% |
| Urology | 2% |
| Plastic Surgery | 1% |
| Dentistry | 1% |
Phase 1 (including bioequivalence studies)
Phase 1 and bioequivalence experience
- 80%Bioequivalent rate
- 177Study cases
- 140Bioequivalent cases
| Therapeutic area | Share |
|---|---|
| Endocrinology | 22% |
| Cardiovascular | 21% |
| Hematology | 14% |
| Gastroenterology | 12% |
| Pain Killer | 11% |
| Nervous System | 8% |
| Immunology | 5% |
| Infectious Disease | 2% |
| Urology | 2% |
| Antibiotics | 2% |
| Ophthalmology | 1% |